![Jesper Zeuthen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jesper Zeuthen
Corporate Officer/Principal chez
University of Aarhus
Profil
Jesper Zeuthen is currently an Associate Professor at the University of Aarhus and an Adjunct Professor at the University of Copenhagen.
He has formerly served as Chairman of Genmab A, Borean Pharma ApS, Zealand Pharma A, LiPlasome Pharma A, Roche Innovation Center Copenhagen A, and TopoTarget UK Ltd. He was also a Research Director at Novo Holdings AS (Denmark) and a Director at Nereus Pharmaceuticals, Inc. and Warren Pharmaceuticals, Inc. Additionally, he served as Managing Partner at BI Technology A.
Postes actifs de Jesper Zeuthen
| Sociétés | Poste | Début |
|---|---|---|
University of Aarhus
 University of Aarhus Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 18/08/2009 |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 18/08/2009 |
Anciens postes connus de Jesper Zeuthen
| Sociétés | Poste | Fin |
|---|---|---|
| TOPOTARGET A/S | Directeur/Membre du Conseil | 23/07/2009 |
BI Technology A/S
 BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | President | 01/02/2009 |
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals drugs and protein engineering services | Président | 16/04/2008 |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Directeur Technique/Scientifique/R&D | - |
| GENMAB A/S | Président | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
41
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genmab A/S
 Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals | Health Technology |
Nereus Pharmaceuticals, Inc.
 Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops therapeutics for cancer, inflammatory, and infectious diseases | Commercial Services |
Borean Pharma ApS
Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals drugs and protein engineering services | Health Technology |
University of Aarhus
University of Aarhus Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
LiPlasome Pharma A/S
 LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, produces and supplies drugs for chemotherapy treatment | Health Technology |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade Develops anti-cancer drugs | Retail Trade |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Warren Pharmaceuticals, Inc.
 Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops tissue-protective technologies | Health Technology |
